Literature DB >> 32297835

Microenvironmental Determinants of Pancreatic Cancer.

Elisabeth Hessmann1, Sören M Buchholz1, Ihsan Ekin Demir2, Shiv K Singh1, Thomas M Gress3, Volker Ellenrieder4, Albrecht Neesse4.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment (TME) that dynamically evolves during tumor progression. The TME consists of different non-neoplastic cells such as cancer-associated fibroblasts (CAFs), immune cells, endothelial cells and neurons. Furthermore, abundant extracellular matrix (ECM) components such as collagen and hyaluronic acid (HA) as well as matricellular proteins create a highly dynamic and hypovascular TME with multiple biochemical and physical interactions among the various cellular and acellular components that promote tumor progression and therapeutic resistance. In recent years, intensive research efforts have resulted in a significantly improved understanding of the biology and pathophysiology of the TME in PDAC, and novel stroma-targeted approaches are emerging that may help to improve the devastating prognosis of PDAC patients. However, none of anti-stromal therapies have been approved in patients so far, and there is still a large discrepancy between multiple successful preclinical results and subsequent failure in clinical trials. Furthermore, recent findings suggest that parts of the TME may also possess tumor-restraining properties rendering tailored therapies even more challenging.

Entities:  

Keywords:  CAF; immune system; pancreatic cancer; tumor microenvironment; tumor stroma

Year:  2020        PMID: 32297835     DOI: 10.1152/physrev.00042.2019

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  44 in total

1.  TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer.

Authors:  Mengyu Tu; Lukas Klein; Elisa Espinet; Theodoros Georgomanolis; Florian Wegwitz; Xiaojuan Li; Laura Urbach; Adi Danieli-Mackay; Stefan Küffer; Kamil Bojarczuk; Athanasia Mizi; Ufuk Günesdogan; Björn Chapuy; Zuguang Gu; Albrecht Neesse; Uday Kishore; Philipp Ströbel; Elisabeth Hessmann; Stephan A Hahn; Andreas Trumpp; Argyris Papantonis; Volker Ellenrieder; Shiv K Singh
Journal:  Nat Cancer       Date:  2021-11-15

Review 2.  Glycolysis in the progression of pancreatic cancer.

Authors:  Xinyao Chang; Xingchen Liu; Haoze Wang; Xuan Yang; Yan Gu
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 3.  Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer.

Authors:  Lennart Versemann; Elisabeth Hessmann; Maria Ulisse
Journal:  Visc Med       Date:  2021-11-19

4.  Nine Pyroptosis-Related lncRNAs are Identified as Biomarkers for Predicting the Prognosis and Immunotherapy of Endometrial Carcinoma.

Authors:  Deku Liang; Min Hu; Qin Tang; Mao Huang; Liangdan Tang
Journal:  Int J Gen Med       Date:  2021-11-12

5.  Proteogenomic characterization of pancreatic ductal adenocarcinoma.

Authors:  Liwei Cao; Chen Huang; Daniel Cui Zhou; Yingwei Hu; T Mamie Lih; Sara R Savage; Karsten Krug; David J Clark; Michael Schnaubelt; Lijun Chen; Felipe da Veiga Leprevost; Rodrigo Vargas Eguez; Weiming Yang; Jianbo Pan; Bo Wen; Yongchao Dou; Wen Jiang; Yuxing Liao; Zhiao Shi; Nadezhda V Terekhanova; Song Cao; Rita Jui-Hsien Lu; Yize Li; Ruiyang Liu; Houxiang Zhu; Peter Ronning; Yige Wu; Matthew A Wyczalkowski; Hariharan Easwaran; Ludmila Danilova; Arvind Singh Mer; Seungyeul Yoo; Joshua M Wang; Wenke Liu; Benjamin Haibe-Kains; Mathangi Thiagarajan; Scott D Jewell; Galen Hostetter; Chelsea J Newton; Qing Kay Li; Michael H Roehrl; David Fenyö; Pei Wang; Alexey I Nesvizhskii; D R Mani; Gilbert S Omenn; Emily S Boja; Mehdi Mesri; Ana I Robles; Henry Rodriguez; Oliver F Bathe; Daniel W Chan; Ralph H Hruban; Li Ding; Bing Zhang; Hui Zhang
Journal:  Cell       Date:  2021-09-16       Impact factor: 66.850

6.  SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.

Authors:  Weiqiang You; Jia Ke; Yufeng Chen; Zerong Cai; Ze-Ping Huang; Peishan Hu; Xiaojian Wu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

7.  Identification of a novel lipid metabolism-related gene signature within the tumour immune microenvironment for breast cancer.

Authors:  Xu Chang; Peng Xing
Journal:  Lipids Health Dis       Date:  2022-05-13       Impact factor: 4.315

8.  Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts.

Authors:  Sonakshi Bhattacharjee; Florian Hamberger; Aashreya Ravichandra; Maximilian Miller; Ajay Nair; Silvia Affo; Aveline Filliol; LiKang Chin; Thomas M Savage; Deqi Yin; Naita Maren Wirsik; Adam Mehal; Nicholas Arpaia; Ekihiro Seki; Matthias Mack; Di Zhu; Peter A Sims; Raghu Kalluri; Ben Z Stanger; Kenneth P Olive; Thomas Schmidt; Rebecca G Wells; Ingmar Mederacke; Robert F Schwabe
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 14.808

Review 9.  [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist].

Authors:  Philipp Mayer; Matthias M Gaida
Journal:  Pathologe       Date:  2021-05-06       Impact factor: 1.011

10.  Bioinformatics and Molecular Insights to Anti-Metastasis Activity of Triethylene Glycol Derivatives.

Authors:  Vidhi Malik; Sukant Garg; Sajal Afzal; Jaspreet Kaur Dhanjal; Chae-Ok Yun; Sunil C Kaul; Durai Sundar; Renu Wadhwa
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.